&lt;i&gt;In Vitro&lt;/i&gt; Antimicrobial Susceptibility of &lt;i&gt;Brucella melitensis&lt;/i&gt; Isolates from Sheep in an Area Endemic for Human Brucellosis in Turkey

Ilhan, Ziya; Solmaz, Hasan; Ekin, İsmail Hakkı

doi:10.1292/jvms.12-0163

Cited by 13 publications

(14 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, Lopez-Merino et al reported that rifampin was less effective than other antibiotics against Brucella strains, and cotrimoxazole showed the poorest activity with an MIC 90 of 8.0 mg/mL [ 19 ]. Furthermore, Ilhan et al also reported a resistance rate of 9.7% to rifampin for B. melitensis and the highest resistance rate (46.3%) was observed for cotrimoxazole [ 20 ]. China is the world’s most populous country and tens of thousands of tons of antibiotics are used annually.…”

Section: Discussionmentioning

confidence: 99%

In vitro antimicrobial susceptibility testing of human Brucella melitensis isolates from Ulanqab of Inner Mongolia, China

Liu

Wang³

et al. 2018

BMC Infect Dis

View full text Add to dashboard Cite

BackgroundBrucellosis is an endemic disease in the Inner Mongolia Autonomous Region of China and Ulanqab exhibits the highest prevalence of brucellosis in this region. Due to the complex nature of Brucellosis, a cure for this disease has proven to be elusive. Furthermore, the reduced susceptibility of Brucella spp. to antimicrobial agents has been reported as a potential cause of therapeutic failure. However, detailed in vitro antimicrobial susceptibility patterns pertaining to Brucella isolates from this region have not yet been published. The aim of this study was to evaluate the antibiotic susceptibility profile of Brucella melitensis clinical isolates from Ulanqab, Inner Mongolia, China.MethodsA total of 85 B. melitesis isolates were obtained from humans in Ulanqab of Inner Mongolia, China; the antimicrobial susceptibility of 85 clinical isolates to nine antibiotics was assessed using the E-test method according to the CLSI (Clinical and Laboratory Standards Institute) guidelines.ResultsAll of the tested isolates were susceptible to minocycline, sparfloxacin, doxycycline, tetracycline, ciprofloxacin, gentamicin and levofloxacin. Resistance to rifampin and cotrimoxazole was observed in 1.0% (1/85) and 7.0% (6/85) of the isolates, respectively. However, rpoB gene mutations were not observed in single isolates exhibiting resistance to rifampin.ConclusionsWe observed that B. melitensis isolates are susceptible to the majority of the tested antibiotics. Furthermore, minocycline and sparfloxacin exhibited extremely high bactericidal effects in relation to the B. melitensis isolates. The sensitivity of commonly used drugs for the treatment of brucellosis should be regularly monitored. To the best of our knowledge, this is the first report of rifampin and cotrimoxazole resistant isolates of B. melitensis in China. In summary, based on the findings from this study, we suggest that antibiotic administration and use should be rationalized to prevent future drug resistance.

show abstract

Section: Discussionmentioning

confidence: 99%

In vitro antimicrobial susceptibility testing of human Brucella melitensis isolates from Ulanqab of Inner Mongolia, China

Liu

Wang³

et al. 2018

BMC Infect Dis

View full text Add to dashboard Cite

show abstract

“…High ciprofloxacin MICs (up to 8 mg/L) have been reported for human and animal strains of Brucella sp. [11,15,19,30,57]. No gyrA mutation has been reported so far in these strains [61].…”

Section: Acquired Resistances To Antibiotics In Brucella Speciesmentioning

confidence: 89%

“…These mutations led to a number of amino acid changes: Val154Phe, Asp526Tyr, Asp526Gly, Asp526Asn, His536Leu, His536Tyr, Arg539Ser, Ser541Leu, and Pro574Leu. A number of studies have reported wide ranges of rifampicin MICs (up to 64 mg/L) in human and animal strains of Brucella sp., with MIC variations between geographic regions and time periods considered [9,11,15,19,22,23,26,30,33,57,58]. In vivo selection of rifampicin-resistant mutants was also reported in a patient who relapsed after treatment with doxycycline and rifampicin [59].…”

Section: Acquired Resistances To Antibiotics In Brucella Speciesmentioning

confidence: 90%

“…Very few studies have reported high doxycycline MICs (up to 32 mg/L) in animal and human strains of Brucella sp. [11,15,17,57]. In some studies, however, high-level MICs may have been related to the use of a high bacterial inoculum rather than true acquired resistance to tetracyclines [15,17].…”

Section: Acquired Resistances To Antibiotics In Brucella Speciesmentioning

confidence: 99%

“…The same holds true for the aminoglycoside streptomycin, with MICs > 64 mg/L in only two studies [9,15], while high MICs to gentamicin have not been reported so far. High MICs to trimethoprim-sulfamethoxazole combination have also been reported [10,13,17,57,58,63,64], but without characterization of the involved mechanisms. The MICs of macrolides, especially erythromycin [11,16,18,30], are highly variable among Brucella strains.…”

Section: Acquired Resistances To Antibiotics In Brucella Speciesmentioning

confidence: 99%

See 2 more Smart Citations

Antibiotic Susceptibility Testing of Brucella Species - Old and New Drugs

Maurin¹

2015

Updates on Brucellosis

View full text Add to dashboard Cite

Brucella species cause brucellosis in humans and animals, a zoonosis that can manifest not only as acute or chronic diseases but also as silent infections persisting throughout life with recurrences potentially occurring after several decades. In vitro and in vivo methods have been developed to evaluate the bacteriostatic and bactericidal activity of antibiotics against Brucella sp. Especially eukaryotic cells and animal models have been used to eval uate the ability of antibiotics, alone or in combination, to eradicate these bacteria from their intracellular reservoir. Although treatment recommendations have been established for common clinical forms of brucellosis, optimized therapeutic alternatives are still need ed for severe forms of the disease, and for infections occurring in young children and pregnant women. Moreover, acquired resistance to first-line treatments of brucellosis is a current concern. This chapter will summarize current knowledge on in vitro and in vivo interactions between Brucella species and antibiotics and new therapeutic strategies that have been evaluated. Keywords: Brucella, brucellosis, antibiotic susceptibility testing, antibiotic resistance, treatment . IntroductionMost Brucella species are highly infectious in humans and thus are considered class biological agents [ -] and potential biological threat agents by the CDC class B [ , ]. Because of a high risk of human infections, especially through inhalation of infectious aerosols, the Brucella cultures should be handled in a biosafety level laboratory. Also, in many countries, detention of these pathogens is now subject to strict regulations. The clinical symptoms of brucellosis are often unspecific. Therefore, the diagnosis may be delayed, especially in geographic areas where the disease is rare and thus often not evoked by physicians in febrile patients. A definite © 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. diagnosis of brucellosis relies on isolation of Brucella sp. from infected patients, mainly from blood samples during the first few weeks following the onset of symptoms. Serological methods lack specificity, and only represent a stopgap for brucellosis diagnosis. PCR-based techniques are useful to detect Brucella DNA in clinical samples, especially in patients with suppurated secondary locations. A specific antibiotic therapy should be started as soon as possible to avoid severe complications including neurological and cardiac involvement , and evolution to a chronic debilitating disease. However, current treatment alternatives are still scarce in adult patients, and even more limited in young children and pregnant women. Although rarely fatal, brucellosis remains a major public health problem worldwide, and a significant economic burden in livestock because of its a...

show abstract

Prevalence of Brucella melitensis and Brucella abortus aminoglycoside-resistant isolates: a systematic review and meta-analysis

Moradkasani,

Goodarzi,

Beig

et al. 2024

Braz J Microbiol

View full text Add to dashboard Cite

<i>In Vitro</i> Antimicrobial Susceptibility of <i>Brucella melitensis</i> Isolates from Sheep in an Area Endemic for Human Brucellosis in Turkey

Cited by 13 publications

References 25 publications

In vitro antimicrobial susceptibility testing of human Brucella melitensis isolates from Ulanqab of Inner Mongolia, China

In vitro antimicrobial susceptibility testing of human Brucella melitensis isolates from Ulanqab of Inner Mongolia, China

Antibiotic Susceptibility Testing of Brucella Species - Old and New Drugs

Prevalence of Brucella melitensis and Brucella abortus aminoglycoside-resistant isolates: a systematic review and meta-analysis

Contact Info

Product

Resources

About